Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07360522 · ClinicalTrials.gov registry record

Data Collection For Adventitious Lung Sounds Algorithm Using Eko Digital Devices in a Clinical Setting

A clinical trial of Lung Diseases, sponsored by Eko Devices.

Active
Registry status
750
Enrollment target
1
Study location

NCT07360522 is a study of Lung Diseases that is active but no longer recruiting, run by Eko Devices. The registered enrollment target is 750 participants, roughly in line with the 715-participant average among 31 other Lung Diseases trials with a reported enrollment target. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07360522, a study of Lung Diseases, is active but no longer recruiting, sponsored by Eko Devices.

ACTIVE NOT RECRUITING
Registry status
750 participants
Enrollment target
1
Study location

Study Summary

The purpose of this research is to collect patient lung sounds in order to develop an artificial machine learning algorithm that can potentially tell a doctor if a patient is at risk of certain lung conditions.

Conditions Studied

Interventions

  • DEVICE Eko digital stethoscopes

Study Locations (1)

Texas

  • Care United Research - Forney

Trial Details

FieldValue
Enrollment Target 750 participants
Start Date 2024-08-23
Est. Completion 2026-03-15

Sponsor

Eko Devices

16 total trials

What the Registry Record Tells You About NCT07360522

The ClinicalTrials.gov registry entry for NCT07360522 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 750 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 715-participant average among 31 other Lung Diseases trials with a reported enrollment target. The listed sponsor is Eko Devices, which has 16 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Lung Diseases appearing as the primary indexed condition, and to 1 intervention - of which Eko digital stethoscopes is the first listed.

NCT07360522 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT07360522 about?

NCT07360522 is a clinical study titled "Data Collection For Adventitious Lung Sounds Algorithm Using Eko Digital Devices in a Clinical Setting". The purpose of this research is to collect patient lung sounds in order to develop an artificial machine learning algorithm that can potentially tell a doctor if a patient is at risk of certain lung conditions.

What is the current status of trial NCT07360522?

This trial is currently active not recruiting. The enrollment target is 750 participants. The study started on 2024-08-23. Estimated completion is 2026-03-15.

What conditions does trial NCT07360522 study?

This clinical trial studies the following conditions: Lung Diseases.

What interventions are being tested in trial NCT07360522?

The interventions under investigation include: Eko digital stethoscopes (DEVICE).

Who is sponsoring clinical trial NCT07360522?

This trial is sponsored by Eko Devices, which has 16 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07360522 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Lung Diseases

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.